Abstract

AbstractBackgroundCachexia is a debilitating complication of cancer characterized by progressive wasting and weakness of skeletal muscles that reduces quality of life and can compromise survival. Many anticancer treatments, such as chemotherapy, also cause muscle wasting, which impairs the response to treatment. Given that many cancer patients present with cachexia at the initiation of treatment, we investigated whether cachectic mice were susceptible to chemotherapy‐induced muscle wasting and to investigate contributing mechanisms, including the dysregulation of microRNAs (miRs).MethodsCachectic colon‐26 (C‐26) tumour‐bearing mice were given 5‐fluourouracil (5‐FU) chemotherapy or vehicle treatment and analysed for muscle mass, fibre size and composition, and miR expression. Mechanisms were validated in vitro using C2C12 cell culture and miR mimics and inhibitors and were confirmed in vivo by injecting muscles of 5‐FU‐treated cachectic mice with recombinant adeno‐associated viral (rAAV) vectors encoding a miR sponge.ResultsIn cachectic tumour‐bearing mice, 5‐FU chemotherapy exacerbated the loss of skeletal muscle mass compared with vehicle treatment (by −12% to −20%, P < 0.05). miR expression profiling, quantitative real‐time PCR, and in vitro analyses revealed contributing mechanisms including miR‐351‐3p‐dependent ERK2 inhibition. Intramuscular injection of rAAV vectors encoding a sponge to reduce miR‐351‐3p expression in 5‐FU‐treated cachectic mice enhanced ERK phosphorylation (+18%, P < 0.05) and increased muscle fibre size (+15%, P < 0.01). Hsa‐miR‐125a‐3p shares similar predicted gene targets as mmu‐miR‐351‐3p, and its inhibition in human muscle cells in vitro prevented 5‐FU‐induced atrophy (P < 0.001) and increased ERK phosphorylation (P < 0.001).ConclusionsThe findings implicate miR‐351‐3p‐mediated ERK2 inhibition as a contributing mechanism in chemotherapy‐induced muscle wasting in mice with cancer cachexia and that its inhibition is a promising adjunct therapy for preserving muscles during cancer treatment.

Highlights

  • Cachexia is the profound weight loss, frailty, and fatigue that affects many cancer patients

  • We focused mechanisms on dysregulated microRNAs because they are important contributing regulators of muscle size[17] and protein turnover,[18] altered miR expression is associated with cancer cachexia[19,20,21] and other conditions of muscle wasting,[22,23] and miR-based therapies are effective and safe to use in vivo.[24]

  • Given that many cancer patients present with cachexia at diagnosis and initiation of anticancer treatment, and because chemotherapy itself can cause muscle wasting and weakness, we investigated whether mice with existing cachexia were susceptible to chemotherapy-induced muscle wasting

Read more

Summary

Introduction

Cachexia is the profound weight loss, frailty, and fatigue that affects many cancer patients. Cachexia is a debilitating complication of cancer characterized by progressive wasting and weakness of skeletal muscles that reduces quality of life and can compromise survival. Many anticancer treatments, such as chemotherapy, cause muscle wasting, which impairs the response to treatment. Given that many cancer patients present with cachexia at the initiation of treatment, we investigated whether cachectic mice were susceptible to chemotherapy-induced muscle wasting and to investigate contributing mechanisms, including the dysregulation of microRNAs (miRs). Intramuscular injection of rAAV vectors encoding a sponge to reduce miR-351-3p expression in 5-FU-treated cachectic mice enhanced ERK phosphorylation (+18%, P < 0.05) and increased muscle fibre size (+15%, P < 0.01). Conclusions The findings implicate miR-351-3p-mediated ERK2 inhibition as a contributing mechanism in chemotherapy-induced muscle wasting in mice with cancer cachexia and that its inhibition is a promising adjunct therapy for preserving muscles during cancer treatment

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call